Ajeeta B. Dash

4.9k citations

23 papers · 3.6k indexed · 1 hit paper · h-index 11

Impact in

Genetics top 0.5%
- Mesenchymal stem cell research
Oncology top 1%
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis

Papers in

Hematology 14
- Multiple Myeloma Research and Treatments 8
- Acute Myeloid Leukemia Research 6
Genetics 5
- Mesenchymal stem cell research 2

Co-authors: Ross Tubo Mary W. Brooks Kornélia Polyák Antoine E. Karnoub George W. Bell Andrew Sullivan Andrea L. Richardson Robert A. Weinberg
Journals: Blood (9 papers)Investigational New Drugs (1 paper)Tissue Engineering (1 paper)Molecular Cell (1 paper)Nature (1 paper)
Partner nations: United States United Kingdom Netherlands

In The Last Decade

Ajeeta B. Dash

22 papers receiving 3.5k citations

Hit Papers

align trajectories log scale

Mesenchymal stem cells within tumour stroma promote breast cancer metastasis 2007 · 2.5k citations

Peers

Countries citing papers authored by Ajeeta B. Dash

Since Specialization

Citations

This map shows the geographic impact of Ajeeta B. Dash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajeeta B. Dash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajeeta B. Dash more than expected).

Fields of papers citing papers by Ajeeta B. Dash

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ajeeta B. Dash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajeeta B. Dash. The network helps show where Ajeeta B. Dash may publish in the future.

Co-authors

The 25 scholars most cited alongside Ajeeta B. Dash, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ajeeta B. Dash Line = papers co-authored together Ajeeta B. Dash links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma HemaSphere ·T.H. Urlings, 造地免田, John Newcomb, رحمانی زاده، داود, Ruud Ruiter, Carlos Bryan-Jiménez, Eric Poma, C. J. Moore, 省志湯浅, Anya Lublinsky, Yuhong Zhang, Pierre Beslay, Michael A. Milhollen, Ajeeta B. Dash, Niels W.C.J. van de Donk, Richard W.J. Groen, Sonja Zweegman, Tuna Mutis	2024	1
2	A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma Blood Cancer Journal ·Wee Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi‐Ankrah, E. E. Newton, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios Α. Dimopoulos, S. Vincent Rajkumar	2023	1
3	MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials Blood ·Bruno Paiva, Irene Manrique, Meletios Α. Dimopoulos, Francesca Gay, Chang‐Ki Min, Sonja Zweegman, Ivan Špıčka, Raphael Teipel, María‐Victoria Mateos, Nicola Giuliani, Michèle Cavo, Suhuan He, Weijun Fu, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash	2022	25
4	P-052: Measurable residual disease (MRD) dynamics during maintenance with ixazomib vs placebo in 1280 newly diagnosed multiple myeloma (NDMM) patients: a pooled analysis of the TOURMALINE-MM3 and -MM4 trials Clinical Lymphoma Myeloma & Leukemia ·Bruno Paiva, Irene Manrique, Meletios Α. Dimopoulos, Francesca Gay, Chang‐Ki Min, Sonja Zweegman, Ivan Špıčka, Raphael Teipel, María‐Victoria Mateos, Nicola Giuliani, Michèle Cavo, Suhuan He, R. PRASERTPHON, Kaveri Suryanarayan, Alexander Vorog, Cong Li, Bingxia Wang, Jose Estevam, Richard Labotka, Ajeeta B. Dash	2022	0
5	DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents Blood ·Soohyung Park, Jurianto Jurianto, A. R. Johns, Dan Zhao, Robert J. Fram, Ajeeta B. Dash, Rafael Bejar	2020	1
6	Prognostic Importance of Measurable Residual Disease (MRD) Kinetics and Progression-Free Survival (PFS) Benefit in MRD+ Patients (Pts) with Ixazomib Vs Placebo As Post-Induction Maintenance Therapy: Results from the Multicenter, Double-Blind, Phase 3 TOURMALINE-MM4 Trial in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Pts Blood ·Bruno Paiva, Irene Manrique, Nicola Giuliani, Michèle Cavo, Christine Rojas, Weijun Fu, María‐Victoria Mateos, Meletios Α. Dimopoulos, Alexander Vorog, Cong Li, Bingxia Wang, Richard Labotka, Ajeeta B. Dash	2020	1
7	Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation European Journal Of Haematology ·Ajeeta B. Dash, 琢磨齋藤, Lei Shen, Bin Li, Deborah Berg, Jianchang Lin, Hervé Avet‐Loiseau, Nizar J. Bahlis, Philippe Moreau, Paul G. Richardson, Alessandra Di Bacco	2020	14
8	TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells Blood ·T.H. Urlings, رحمانی زاده، داود, Jack P. Higgins, Erin K. Willert, John Newcomb, Ajeeta B. Dash, Niels W.C.J. van de Donk, Sonja Zweegman, Tuna Mutis	2020	12
9	P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients Journal of Crohn s and Colitis ·Frank Wagner, John Mansfield, Christian Geier, Ajeeta B. Dash, Valentin Grigoraș, Marina Lemos Sartori, Annemarie Lekkerkerker, Taiying Lu	2020	6
10	A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara) Blood ·Shaji Kumar, Robert F. Cornell, Ola Landgren, Sikander Ailawadhi, Jack P. Higgins, Erin K. Willert, Roger J. Waltzman, Jianchang Lin, Yuhong Zhang, Anya Lublinsky, Ajeeta B. Dash, Michael J. Hanley, Dušan Todorović, Puwit Charoenchua, V.V. Tikhonov, Richard Labotka, John Newcomb, Alexander Vorog	2019	7
11	Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, Nitin Chandrashekhar Adgaonkar, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Mutembei Henry M'Ïkiugu, Douglas V. Faller, Michael R. Savona	2018	157
12	Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors Investigational New Drugs ·A. Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Carrie B. Lee, R. Donald Harvey, Roger B. Cohen, Farhad Sedarati, 朱佳琦, Hélène M. Faessel, Ajeeta B. Dash, Bruce J. Dezube, Douglas V. Faller, Afshin Dowlati	2018	62
13	Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies Blood ·Bin Li, Konda Aravind Kumar, Lei Shen, Peijie Hou, Zhenqiang Su, Alessandra Di Bacco, Jin‐Liern Hong, Aaron Galaznik, Ajeeta B. Dash, Dan Tan Lai Chan, Paul Dolin, Sándor Szalma	2018	1
14	Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia (AML) Blood ·Ronan Swords, Steven Coutré, Michael B. Maris, Joshua F. Zeidner, James M. Foran, José C. Cruz, Harry P. Erba, Jesús G. Berdeja, Wayne Tam, Saran Vardhanabhuti, José Luis Rénique Caycho, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Michael R. Savona	2016	7
15	Pevonedistat (MLN4924), an Investigational, First-in-Class NAE Inhibitor, in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Considered Unfit for Conventional Chemotherapy: Updated Results from the Phase 1 C15009 Trial Blood ·Ronan Swords, Michael R. Savona, Michael B. Maris, Harry P. Erba, Jesús G. Berdeja, James M. Foran, Zhaowei Hua, Hélène M. Faessel, Ajeeta B. Dash, Farhad Sedarati, Bruce J. Dezube, Bruno C. Medeiros	2014	10
16	Mesenchymal stem cells within tumour stroma promote breast cancer metastasis Nature ·Antoine E. Karnoub, Ajeeta B. Dash, Veyedalamula Varalakshmi Surekha, Andrew Sullivan, Mary W. Brooks, George W. Bell, Andrea L. Richardson, Kornélia Polyák, Ross Tubo, Robert A. Weinberg Hit paper breakdown →	2007	2507
17	Systematic Analysis of Reportedly Distinct Populations of Multipotent Bone Marrow-Derived Stem Cells Reveals a Lack of Distinction Tissue Engineering ·Tracey Lodie, David Funck, Aprilian Nurangga Saputra, Chufa He, Ajeeta B. Dash, Jennifer Clarke, Bilikis Mosunmola JIMOH, Lamya S. Shihabuddin, Ross Tubo	2002	104
18	Molecular genetics of acute myeloid leukaemia Best Practice & Research Clinical Haematology ·Ajeeta B. Dash, D. Gary Gilliland	2001	109
19	Pim-1 Kinase and p100 Cooperate to Enhance c-Myb Activity Molecular Cell ·Joel Johansson, Päivi J. Koskinen, Aroutunov, Eeva-Marja Rainio, 辰夫東海林, Ajeeta B. Dash, Robert N. Eisenman, Scott A. Ness	1998	228
20	Effect of oral theophylline on resting energy expenditure in normal volunteers. Thorax ·Ajeeta B. Dash, Anil Agrawal, J. B. Hill, John Moxham, J Ponte	1994	7

About Ajeeta B. Dash

Ajeeta B. Dash is a scholar working on Hematology, Genetics, Oncology, Molecular Biology and Pathology and Forensic Medicine, having authored 23 papers that have together received 3.6k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (8 papers), Acute Myeloid Leukemia Research (6 papers), Protein Degradation and Inhibitors (5 papers), Ubiquitin and proteasome pathways (5 papers), Peptidase Inhibition and Analysis (3 papers), Monoclonal and Polyclonal Antibodies Research (3 papers), Cancer Mechanisms and Therapy (2 papers) and Mesenchymal stem cell research (2 papers). The work is most often cited by research in Genetics (1.0k citations), Oncology (1.8k citations), Cancer Research (808 citations), Hematology (448 citations) and Immunology (523 citations). Ajeeta B. Dash has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Ross Tubo, Mary W. Brooks, Kornélia Polyák, Antoine E. Karnoub, George W. Bell, Andrew Sullivan, Andrea L. Richardson, Robert A. Weinberg, Scott A. Ness and D. Gary Gilliland. Their work appears in journals such as Blood, Investigational New Drugs, Tissue Engineering, Molecular Cell and Nature.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact